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Abstract
Background: The polyether antibiotic Salinomycin (Sal) is regarded as an inhibitor of cancer stem cells. Its
effectiveness on human colorectal cancer (CRC) cells in vitro has been demonstrated before. The aim of this
study was to establish a murine model to investigate the effectiveness of Sal in vivo. Furthermore, we investigated
the impact of Sal on Wnt/β-catenin signaling in human CD133+ CRC cells.
Methods: The two murine CRC cell lines MC38 and CT26 were used to analyze the impact of Sal on tumor cell
proliferation, viability, migration, cell cycle progression and cell death in vitro. For in vivo studies, CT26 cells were
injected into syngeneic BALB/c mice to initiate (i) subcutaneous, (ii) orthotopic, or (iii) metastatic CRC growth. Sal was
administered daily, 5-Fluoruracil served as a control. For mechanistic studies, the CD133+and CD133- subpopulations of
human CRC cells were separated by flow cytometry and separately exposed to increasing concentrations of Sal. The
impact on Wnt/β-catenin signaling was determined by Western blotting and quantitative PCR.
Results: Sal markedly impaired tumor cell viability, proliferation and migration, and induced necrotic cell death in vitro.
CRC growth in vivo was likewise inhibited upon Sal treatment. Interference with Wnt signaling and reduced expression
of the Wnt target genes Fibronectin and Lgr5 indicates a novel molecular mechanism, mediating anti-tumoral effects
of Sal in CRC.
Conclusion: Sal effectively impairs CRC growth in vivo. Furthermore, Sal acts as an inhibitor of Wnt/β-catenin signaling.
Thus, Salinomycin represents a promising candidate for clinical CRC treatment.
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Background
The pro-apoptotic effects of the polyether antibiotic
Salinomycin (Sal) in cancer stem cells were first
described by Gupta and co-workers [1] and confirmed
in succeeding studies in cancer cells of solid and non-
solid malignancies (reviewed in [2, 3]). The precise
mode of action of Sal is still not completely understood
and it is plausible that it differs among the diverse
types of cancer cells.
Colorectal cancer (CRC) is the third leading cause of
death in the western world [4]. Given that patients’
prognosis in advanced stage of disease is limited and
colorectal liver metastases are the most frequent cancer-
related death, innovative therapeutic approaches are of
utmost importance. The impact of Sal on CRC cells has
been already demonstrated [5–7]. In vitro, Sal reduces
the CD133+ subpopulation of human CRC cells and
inhibits epithelial-mesenchymal transition (EMT) [5].
The effect of Sal on CRC has been further explained by
induction of autophagy and accumulation of reactive
oxygen species [6, 8]. However, there are no data avail-
able analyzing the impact of Sal on CRC in vivo.
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Hence, the aim of this study was to establish a mouse
model to investigate the effectiveness of Sal against CRC
growth in vivo. Furthermore, we analyzed the impact of
Sal on Wnt signaling in human CD133+and CD133-
CRC cells. Aberrant Wnt signaling is regarded as crucial
for the oncogenesis of CRC [9, 10] and inhibitory effects
of Sal on Wnt signaling in other types of cancer but not
CRC have been demonstrated before [11].
Methods
Cell lines and culture
The murine CRC cell line MC38 [12, 13] was provided
by H. Abken (University of Cologne, Germany). CT 26
cells were purchased from the American Type Culture
Collection (sub-clone ATTC® CRL2638™) [13]. The
human CRC cell line SW620 [14, 15] was obtained
from (ATCC); HT29 [15] cells were purchased from
the Leibniz Institute DSMZ – German Collection of
Microorganisms and Cell Cultures. Cells were cultured
in DMEM (Sigma Aldrich) and RPMI 1640 medium
(Invitrogen), respectively, supplemented with 10% fetal
calf serum, penicillin (50 U/ml) and streptomycin
(50 mg/l) at 37°C and 5%CO2.
Chemicals and antibodies
Sal and 5-FU were purchased from Sigma Aldrich.
Sal was dissolved in dimethyl sulfoxide (DMSO) for
in vitro analysis [16] or in corn oil for in vivo applica-
tions [17]. 5-FU was dissolved in phosphate buffered
saline (PBS). Stock solutions were stored at -20°C. The
CD133 antibody for flow cytometry and cell sorting
was purchased from Miltenyi (clone AC133). Anti-
bodies for cleaved (c-) PARP, LRP6 (C47E12), phos-
phorylated (P-) LRP6 (Ser1490), β-Actin, and β-Tubulin
(TU-20) for protein analysis were obtained from Cell
Signaling Technology.
Flow cytometric analysis and cell sorting for CD133+/- cells
Analysis of CD133 positivity was performed according
to the manufacturers instructions and as described
before [18]. In brief, cells were washed with PBS and
stained with a Phycoerythyrin (PE)-conjugated CD133
antibody. Signal enhancement was performed by a two-
step FASER procedure (Fluorescence Amplification by
Sequential Employment of Reagents). Appropriate
isotype antibodies served as control. Cell sorting was
performed on a FACS Aria II (Beckton Dickinson).
Representative setups before cell sort are depicted
in Additional file 1: Figure S1 A + B. The purity of
CD133+/CD133- cells was analyzed before the experi-
ments were performed (see Additional file 1: Figure S1
C + D). CD133+/CD133- cells were maintained in culture
for one passage after sorting.
RNA isolation and real-time PCR
Total RNA from tumor cells and tumor tissues was iso-
lated by an RNA extraction kit (Qiagen). cDNA synthe-
sis and real-time (RT)-PCR were performed using the
first strand cDNA synthesis kit (Fermentas) and SYBR
Green Master Mix kit (Roche) applying specific primers
for human or murine Cyclin D1, Fibronectin, lymphoid
enhancer-binding factor 1 (LEF-1) and leucine-rich-
repeat-containing G-protein-coupled-receptor 5 (Lgr5).
Expression rates of the genes of interest were normal-
ized to the expression of glyceraldehy-3-phosphat-de-
hydrogenase (GPDH). Primer sequences are listed in
Additional file 2: Table S1.
Western blotting
After drug treatment for 48 h nuclear protein was
isolated (Life Technologies). Protein content was deter-
mined applying the BCA Protein Assay Kit (Life Tech-
nologies). Equal amounts of protein were separated by
10% SDS-PAGE and transferred to PVDF membranes
(Milipore). The membranes were incubated overnight
with primary antibodies against human LRP6, P-LRP6,
and β-catenin. After washing, membranes were incu-
bated and developed with a horseradish peroxidase-
conjugated secondary antibody (Life Technologies).
β-Tubulin served as internal control. Densitometry
quantitative analysis was performed applying Image J
software (NIH).
Proliferation
5 × 103 murine or human CRC cells were cultured in 96-
well flat bottom plates. Cells were exposed to increasing
concentrations of Sal (1, 2, 5 and 10 μM), to 1 μM 5-FU
alone, or to combined Sal and 5-FU for different time
periods: either for 24 or 48 h under treatment, or add-
itionally cultured in medium alone for another 24 or
48 h. Cell proliferation was measured using the WST-1
assay, which is based on the cleavage of the tetrazolium
salt WST-1 into formazan by healthy cells. After the
end of treatment, WST-1 reagent (Roche) was added,
followed by further incubation for 4 h. Formazan for-
mation was quantified by measuring the absorbance at
450 nm according to the manufaturer’s instructions.
Migration
Murine CRC cell migration was further analyzed using
an in vitro scratch assay as described before [19]. In
brief, 0.5 × 106 MC38 and CT26 cells were cultured in 6-
well plates until confluence. A scratch was created in the
middle of the monolayer and cells were treated with
either Sal or 5-FU alone, or combined Sal and 5-FU. Cell
migration was assessed by phase-contrast microscopy
(Zeiss, Jena, Germany) and images were captured at the
beginning of treatment and after 24 and 48 h. Open
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wound area was calculated using TScratch software
(Swiss Federal Institute of Technology Zurich) as de-
scribed before [20].
Tumor cell migration was further investigated using
transwell-chambers (Cell Biolabs) equipped with an 8 μm
pore polycarbonate membrane according to Boyden [21].
1 × 105 cells were seeded in the upper compartment of the
membrane in culture medium without fetal calf serum.
The lower compartment of the chamber was filled with
culture medium containing 20% fetal calf serum. Cells
were cultured in the absence or presence of either Sal
or 5-FU alone or combined Sal and 5-FU for 48 h and
analyzed immediately or further incubated with fresh
culture medium for another 48 h. Afterwards the cells
in the upper compartment of the membrane were re-
moved using a cotton swab. Membranes were stained with
crystal violet solution, migrated cells on the lower side of
the membrane were isolated from the membrane and
quantified by measurement of the absorbance at 540 nm
according to the manufaturer’s instructions.
Invasion
Tumor cell invasiveness was analyzed by seeding 1 × 105
cells in Matrigel-coated membranes of transwell-chambers
(Cell Biolabs) according to the manufaturer’s instructions
and as described before [22]. Tumor cell invasion assay
was further performed as described for tumor cell migra-
tion assay (see above).
Cell death
Cells were analyzed for apoptosis, late apoptosis or
necrosis induction following exposure to either Sal or
5-FU alone or combined Sal and 5-FU for 24 h applying
the AnnexinV apoptosis detection kit (BD Biosciences)
according to the manufacturer’s instructions as previ-
ously described [16, 23]. AnnexinV positive cells were
regarded as apoptotic cells; AnnexinV/PI positive cells
were regarded as late apoptotic and PI positive cells
were regarded as necrotic cells. Cell death was further
evaluated by quantification of DNA fragmentation in
cultured MC38 and CT26 cells using the HT Titer
TACS Assay Kit (Trevigen) according to the manufac-
turer’s instructions and as described before [24]. Tumor
cell death was analyzed applying the Lactate dehydro-
genase (LDH) Cytotoxicity Assay Kit (Thermo Fisher)
following the manufacturer’s protocol and as described
before [25].
Cell cycle analysis
Cell cycle analysis was performed after exposure to either
Sal, 5-FU or Sal and 5-FU as indicated above for 24 h
applying the CellTest Plus Reagent Kit (BD Biosciences)
according to the manufaturer’s instructions as described
before [23]. Analysis was performed using the Mod Fit
LT Software (Verity House Software).
Animal models and treatment
Animal experiments were carried out in 6–10 week-old
BALB/c-mice purchased from Charles River Laboratories.
Animals were housed under standard conditions with free
access to food and water under constant environmental
conditions with a 12-h day-night-cycle. Isoflurane was
used for inhalation anesthesia. For a subcutaneous tumor
model, 1 × 106 CT26 cells were injected in 50 μl Matrigel
(BD Biosciences) into the flank. After 7 days the animals
were randomized into 5 treatment groups. The animals
were treated daily either with corn oil (control group),
8 mg/kg 5-FU, 4 mg/kg Sal or a combination of 4 mg/kg
Sal and 8 mg/kg 5-FU intraperitoneally. Tumor volume
was assessed daily during chemotherapy for a total of
14 days.
For the orthotopic CRC model, an abdominal midline
incision was performed, the cecum exposed, and 0.5 ×
106 CT26 cells (in 50 μl Matrigel) were injected into the
cecal wall. Afterwards, the cecum was rinsed with dis-
tilled water to kill leaking tumor cells and repositioned
into the abdomen. Alternatively, to assess the efficacy of
Sal treatment in colorectal liver metastases, after laparot-
omy the portal vein was exposed and 0.5 × 106 CT26
were injected into the vein. The abdomen was closed
using PDS 6-0 running suture. The skin was closed
using a 7 mm skin stapler. Mice were checked routinely
every day. Explorative laparotomy was performed after 5,
7 and 21 days to evaluate tumor growth during further
treatment. Adequate tumour growth was observed after
7 days, and the animals were randomly divided into 5
groups. After end of treatment, mice were sacrificed by
cervical dislocation, tumors were harvested, tumor vol-
ume assessed and tumor tissue was either snap frozen
in liquid nitrogen or embedded in paraffin for further
analysis. Based on H&E staining, the metastatic area
within the livers was determined morphometrically
applying Image J software. 20 pictures from each H&E
stained slide (10 slides per animal) were randomly
taken and the metastatic lesions marked. Pixels within
the marked areas were related to the overall pixel count
by Image J software and means ± SD were calculated
and expressed as percentage of metastatic area in cor-
relation to the whole liver.
Terminal desoxynucleotidyl transferase (dUTP) nick end
labeling (TUNEL) assay
TUNEL assay for apoptosis detection was performed on
tissue slides after removal of paraffin applying the Dead-
End Fluorometric TUNEL system (Promega) according
to the manufaturer’s instructions.
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Immunohistochemistry
Paraffin fixed tissue samples were cut into sections of
5 μm and routine hematoxylin and eosin (H&E) staining
was performed to evaluate histomorphological features.
Statistical analysis
Statistical analysis was performed using GraphPadPrism
6. Student’s t-test or ANOVA analysis were applied as
appropriate. For all in vivo experiments, we gained for
an effect (Cohen d) < 2. We supposed an effect d (d =Δ/σ
with Δ = relevant difference; σ = standard deviation) of 1.5.
Hence, we needed 9 animals per group to confirm this
effect α = 0.05 with a power of 80%. We calculated a
fault rate of n = 3 animals per group. Student’s t-test
was used for analysis.
Differences were regarded statistically significant with
p < 0.05 compared to untreated cells which are indicated
as “control” below. Results were expressed as mean ± SD
of at least three independent experiments.
Results
Salinomycin-exposure causes sustained impairment of
tumor cell proliferation
MC38 and CT26 cells were exposed to increasing concen-
trations of Sal (1–10 μM) and 5-FU (1 μM) or to a com-
bination of Sal and 5-FU for 24 and 48 h. Alternatively,
the cells were further incubated for another 24 or 48 h
** **
**
****
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Fig. 1 Impaired murine tumor cell proliferation after treatment with Salinomycin. 5 × 103 MC38 (a + b) and CT26 (c + d) cells were cultured in
microtitre plates in the absence or presence of 1 μM 5-FU, increasing concentrations of Salinomycin (1 μM, 2 μM, 5 μM and 10 μM) and a
combination of 5-FU and Salinomycin. Treatment was performed either for 24 h and 48 h or for another 24–48 h with fresh medium. Tumor
cell proliferation was performed using the WST-1 assay. Results are displayed as summary of at least 3 independent experiments as mean ± SD;
*p < 0.05 and **p < 0.001 compared with control
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after the medium was changed. As demonstrated in Fig. 1,
Sal-treatment significantly reduced tumor cell prolifera-
tion dose-dependently even after lapse of the agent in
both MC38 (A + B) and CT26 cells (C +D). Combined
treatment with Sal and 5-FU did cause comparable results
without an additive synergistic anti-proliferative effect
(Additional file 3: Figure S2).
Reduced tumor cell migration and invasion after
Salinomycin-treatment
After demonstrating the anti-proliferative effect of Sal on
murine CRC cells, we next investigated the impact of Sal
on tumor cell migration and invasion. Impaired migration
of MC38 and CT26 cells was visualized applying a scratch
assay after 24 and 48 h of treatment (Fig. 2 a + b). After
48 h open wound area was clearly increased after treat-
ment with Sal (Fig. 2 c + d). Combined treatment resulted
in comparable results (Additional file 4: Figure S3 A-D).
To further quantify the effects of Sal on migration, we
used a transwell-assay. Sal significantly decreased trans-
membrane migration of MC38 or CT26 cells after treat-
ment for 48 h in a dose-dependent manner (Fig. 2 e + f).
Further incubation for another 48 h revealed sustained
impairment of tumor cell migration (Fig. 2g). Murine CRC
cell invasion through an artificial extracellular matrix using
Matrigel-coated membranes was likewise significantly
impaired in response to Sal administration (Fig. 2h + i) even
after lapse of the agent (Fig. 2j).
Combined treatment with 5-FU and Sal –resulted in simi-
lar effects on tumor cell migration and invasion compared to
treatment with Sal alone (Additional file 4: Figure S3 E-H).
Salinomycin induces death of CRC cells
We further analyzed whether Sal induces cell death in
MC38 and CT26 cells. As demonstrated in Fig. 3, exposure
to Sal was associated with an increased amount of necrotic
cells (AnnexinV/PI positive) compared to control or 5-FU-
treatment. This effect was dose-dependent in both MC38
(Fig. 3a) and CT26 cells (Fig. 3b). Exposure to Sal likewise
resulted in increased DNA fragmentation in MC38 and
CT26 cells, respectively (Fig. 3c + d). We further analyzed
cleaved poly ADP ribose polymerase (c-PARP) production
upon treatment with Sal. Exposure to increasing concen-
trations of Sal resulted in an increased production of c-
PARP (Fig. 3e + f). Cell death was also examined in a LDH
release assay. As demonstrated in Fig. 3g and h, treatment
with Sal resulted in a dose-dependent increase of LDH
release in murine tumor (Fig. 3g) and CT26 cells (Fig. 3h).
The combination of Sal and 5-FU resulted in equi-
valent effects on tumor cell death (Additional file 4:
Figure S3 I + J). We further performed cell cycle analyses
of MC38 and CT26 cells after treatment with Sal. The
results are summarized in the supplementary results
section within the Appendix (see below).
Salinomycin inhibits growth of murine CRC in vivo by
induction of apoptosis
To investigate the impact of Sal on CRC growth in vivo,
three CRC models (subcutaneous, orthotopic and hetero-
topic) were applied. Nine animals were initially treated in
each group with either daily Sal, 5-FU or a combination of
Sal and 5-FU for 2 weeks (see Fig. 4a). Chemotherapy was
well tolerated as documented by general health status of
the animals and body weight during the treatment. For
analysis of the subcutaneous tumor model, we had to
remove three animals out of the control group and two
animals out of the 5-FU group due to excessive tumor
growth. In the orthotopic and liver spread model, all
animals were included into the analysis.
In the subcutaneous tumor model, Sal significantly
inhibited CRC growth. This growth-inhibiting effect was
more pronounced compared to treatment with 5-FU
alone. Combined treatment with Sal and 5-FU did not
result in an additional growth-inhibiting effect (Fig. 4b).
Sal likewise inhibited orthotopic tumor growth in the
cecum of mice. Sal-treated animals presented with smaller
tumors compared to 5-FU-treated animals. Combined
treatment with Sal and 5-FU did not cause further growth
inhibition (Fig. 4c).
A model of colorectal liver spread likewise confirmed
the effectiveness of Sal-treatment on CRC in vivo. Sal
alone or in combination with 5-Fu resulted in markedly
reduction of metastatic liver spread compared to animals
treated either with corn oil (control group) or 5-FU
alone (Fig. 4d-f ).
We further investigated whether Sal induces apoptosis
in CRC in vivo, which was performed on paraffin embed-
ded tumor tissue slides by TUNEL assay. As demonstrated
in Fig. 4g treatment with Sal alone or in combination with
5-FU resulted in an increased amount of apoptotic tumor
area compared to 5-FU alone after 2 weeks of treatment.
Impact of Salinomycin on human CD133+/CD133- CRC cells
After establishing an in vivo model to study the effective-
ness of Sal in murine CRC, we sought to determine mech-
anisms mediating Sal’s anti-tumorigenic effects in human
CRC. It is acknowledged that Sal decreases the proportion
of CD133+ tumor cells, regarded as tumor stem-like cells
[5]. Therefore, we analyzed the impact of Sal on human
CD133+/CD133- CRC cells. To this end, the CD133 ex-
pression of seven different human CRC cells (LS174T,
HCT116, DLD1, SW480, SW620, CaCo2 and HT29) was
analyzed. Only two cell lines (SW620 and HT29) showed
a definable proportion of CD133+ cells. CD133+/CD133-
cells were separated by flow cytometry after staining with
an appropriate antibody to detect CD133. Afterwards,
cells were further cultured separately for one more pas-
sage and used for additional experiments.
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Salinomycin impairs proliferation of human CD133+/CD133-
CRC cells and induces cell death
Unsorted and CD133+/CD133- SW620 und HT29 were ex-
posed to increasing concentrations of Sal or 5-FU for 48 h.
Cell proliferation was analyzed using the WST-1 assay. As
demonstrated in Fig. 5a + b Sal-treatment resulted in a dose-
dependent impairment of tumor cell proliferation in unsorted,
CD133+ and CD133- SW620 and HT29 cells. (Fig. 5a + b).
Fig. 2 Salinomycin reduces migration and invasion of murine colorectal cancer cells. To visualize tumor cell migration 0.5 × 106 MC38 (a) and
CT26 (b) cells were cultured in 6-well plates until confluence. A scratch was created in the middle of the monolayer and cells were treated with
1 μM 5-FU or increasing concentrations of Sal (1 μM, 2 μM, 5 μM and 10 μM). Cell migration was assessed by phase-contrast microscopy and images were
captured at the beginning of treatment and after 24 and 48 h at a magnification of 100. The open wound area after 48 h in cultured MC38 (c) and CT26
cells (d) was calculated and displayed as a summary of 3 independent experiments as mean ± SD; * p< 0.001 compared with control. For transwell-analysis
of tumor cell migration 1 × 105 MC38 or CT26 cells were seeded in 6-well plates equipped with a transwell insert and exposed to 1 μM 5-FU, increasing
concentrations of Salinomycin (1 μM, 2 μM, 5 μM and 10 μM) and a combination of 5-FU and Salinomycin. After 48 h membranes were stained with crystal
violet solution and migrated cells were isolated from the lower side of the membrane and quantified by ELISA reader (e + f). To assess sustained effects of
Salinomycin on tumor cell migration, the cells were treated for 48 h as indicated above and further cultured for another 48 h after lapse of the agent (g).
Alternatively, MC38 and CT26 were cultured in Matrigel-coated transwell inserts. After 48 h or further incubation for another 48 h with fresh culture
medium the number of invasive migrated cells was quantified as described above (h-j). Results are shown as representative images of
stained membranes at a magnification of 100 or as summary of at least 3 independent experiments as mean ± SD; * p < 0.05 and
** p < 0.001 compared with control
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Fig. 4 Inhibition of murine colorectal cancer growth in vivo by Salinomycin. Colorectal cancer growth in BALB/c-mice was induced through injection
of CT26 cells. Cells were either injected subcutaneously into the flank of the animals, into the wall of the cecum to induce orthotopic tumor growth or
into the portal vein to induce metastatic spread. After 1 week, treatment with either 5-FU, Salinomycin or 5-FU and Salinomycin was performed (a). b
After 2 weeks of treatment, Salinomycin significantly inhibited colorectal cancer growth in the subcutaneous tumor model compared to control. Scale
bars, 15 mm. c Orthotopic colorectal cancer growth was also statistically significant abolished after treatment with Salinomycin for 2 weeks. Results are
shown as mean tumor volume ± SD, * p < 0.05, ** p < 0.001 compared with control. d-f The distribution of metastatic colorectal cancer spread in the
liver of mice (indicated as #) was also markedly reduced after treatment with Salinomycin. Results are shown as representative images of CRC liver
spread, H&E stained sections or mean of the percentage of metastatic area ± SD of 9 individual experiments, * p < 0.05. g TNUEL assay was performed
to investigate the amount of apoptotic cells within the explanted murine tumors. After removal of paraffin, slides were stained with TUNEL reagents
according to the manufacturers instructions. The displayed result is a representative image of an orthotopic colorectal cancer specimen
(See figure on previous page.)
Fig. 3 Induction of cell death of murine colorectal cancer cells after treatment with Salinomycin. 0.5 × 106 MC38 (a) or CT26 (b) cells were seeded
in 6-well plates and grown until confluence following exposure to 1 μM 5-FU and increasing concentrations of Salinomycin (1 μM, 2 μM, 5 μM
and 10 μM) for 24 h. Detection of cell death was performed using AnnexinV-FITC and PI staining and cells analyzed by flowcytometry. Cell death
was further determined by quantification of DNA fragmentation (c + d), c-PARP production (e + f) and LDH release assay (g + h). Results are
displayed as representative dot blots or as summary of at least 3 independent experiments; * p < 0.05 compared with control
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Next, we investigated whether Sal exerts its anti-
proliferative effects on human CD133+/CD133- cells by
induction of cell death. Therefore, unsorted and CD133+/-
SW620 and HT29 cells were exposed to Sal or 5-FU as
indicated above for 24 h. Cell death was investigated using
AnnexinV and PI staining. As depicted in Fig. 5c + d
induction of necrotic cell death (AnnexinV/PI double
positive cells) by Sal was likewise observed in unsorted
and CD133+/CD133-cells.
Salinomycin interferes with Wnt-signaling in CD133+/CD133-
human CRC cells
To delineate some of the molecular effects of Sal in human
CD133+and CD133- CRC cells, we analyzed Wnt signaling
**
**
**
** **
**
**
*
*
*
*
*
a
b
c
d
Fig. 5 Salinomycin reduces proliferation and induces cell death of human CD133 colorectal cancer cells after treatment with Salinomycin. 5 × 103
SW620 or SW620-CD133+/CD133- (a) and HT29 or HT29-CD133+/CD133- (b) cells were cultured in microtitre plates in the absence or presence of
1 μM 5-FU or increasing concentrations of Salinomycin (1, 2, 5 and 10 μM). Treatment was performed for 48 h. Tumor cell proliferation was investigated
using the WST-1 assay. Results are displayed as summary or at least 3 independent experiments as mean ± SD; * p < 0.05 and ** p < 0.001 compared
with control. For cell death detection 0.5 × 106 SW620 or SW620-CD133+/CD133- (c) and HT29 or HT29-CD133+/CD133- (d) cells were cultured
in 6-well plates in the absence or presence of 1 μM 5-FU or increasing concentrations of Salinomycin (1, 2, 5 and 10 μM). AnnexinV/PI staining
was performed and cells were analyzed by flowcytometry. Results are displayed as summary or at least 3 independent experiments as mean ± SD;
*p < 0.05 compared with control
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after Sal-treatment. As demonstrated in Fig. 6, treatment
with Sal interferes with Wnt signaling cascade in both
unsorted and CD133+/CD133- SW620 cells. Sal-treatment
resulted in reduced LRP6 protein levels and inhibited
LRP6-phosphorylation (Fig. 6). When analyzing unsorted
and CD133+/CD133- HT29 cells, similar effects of Sal on
Wnt-signaling were found (Additional file 5: Figure S4).
Next, we analyzed if the inhibitory effects of Sal on Wnt
signaling cascade also result in alterations of mRNA
expression of target genes of the Wnt/β-catenin pathway.
Therefore, we analyzed the mRNA expression levels of
Cyclin D1, LEF-1, Fibronectin and Lgr5 using quantitative
PCR after 24 h of treatment. In both CD133+ and CD133-
SW620 cells, we observed a decreased expression of
LRP6
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Fig. 6 Treatment with Salinomycin interferes with Wnt/β-catenin signaling in human CD133+/CD133- colorectal cancer cells. The impact of
Salinomycin treatment on the Wnt/β-catenin signaling pathway in SW620 CD133+/CD133- cells was investigated. For protein expression analysis
1 × 106 total SW620 (a), SW620-CD133+ (b) or SW620-CD133- (c) cells were cultured in 6-well plates in the absence or presence of 1 μM 5-FU or
increasing concentrations of Salinomycin (1, 2, 5 and 10 μM). After protein extraction western blotting was performed using specific antibodies
against total LRP6 and phosphorylated (P-LRP6). Results are displayed as western blot analysis of LRP6 and P-LRP6 (up) with densitometry quantitative
analysis (down). * p < 0.05, ** p < 0.001 compared to control
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Fig. 7 Salinomycin down-regulates the mRNA expression of Fibronectin and Lgr5 in human CD133+/CD133- colorectal cancer cells. The mRNA
expression levels of Fibronectin (a + b) and Lr5 (c + d) in CD133+/CD133- SW620 and CD133+/CD133- HT29 cells were measured by quantitative
PCR after treatment with1 μM 5-FU or increasing concentrations of Salinomycin (1, 2, 5 and 10 μM). * p < 0.05, ** p < 0.001 compared to control
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Fibronectin in a dose-dependent manner after exposure
to Sal (see Fig. 7a). Reduced expression of Fibronectin
was also observed in CD133+ SW620 cells after expos-
ure to 5-FU. Likewise, a reduced mRNA expression of
Fibronectin was observed in CD133+and CD133- HT29
cells after treatment with Sal (Fig. 7b).
Regarding the expression of Lgr5 mRNA, we also ob-
served a decreased expression in CD133+/CD133- SW620
and HT29 cells The dose-dependent decreased expression
of Lgr5 mRNA was more pronounced in CD133+ and
CD133- HT29 cells compared to CD133+/CD133-
SW620 cells (see Fig. 7c + d). There were no consistent
changes in the mRNA expression of Cyclin D1 and LEF-1
(see Additional file 6: Figure S5).
Discussion
In this study we demonstrate that Sal exerts a growth-
inhibiting effect on murine CRC in vivo. Furthermore,
we provide evidence that the pro-apoptotic effect of Sal
on human CD133+ CRC cells is associated with im-
paired Wnt signaling and reduced expression of Wnt
target genes.
The potential of Sal to treat CRC has been demon-
strated in vitro before [5, 6, 8]. However, the evidence
for the effectiveness of Sal in CRC in vivo is still missing.
We therefore established a murine model to investigate
the impact of Sal on CRC in vivo. First, we demonstrated
that Sal exerts its pro-apoptotic effect in two murine
CRC cell lines in a dose-dependent manner. This is
accompanied by inhibition of tumor cell migration and
invasion. Interestingly, in contrast to other observations
before, an additive synergistic effect of Sal and 5-FU in
vitro was not observed [26–28].
The obtained data providing the effectiveness of Sal in
murine CRC in vitro encouraged us to establish an in
vivo-model for CRC. First, we induced subcutaneous CRC
growth in BALB/c-mice. Treatment with Sal resulted in
inhibition of tumor growth compared to control or 5-FU-
treatment. Orthotopic tumor growth in the cecum of the
mice was likewise abolished after treatment with Sal. Add-
itionally, Sal inhibited colorectal spread in the liver of
mice. Treatment with Sal alone or in combination with 5-
FU was superior combined to 5-FU alone. Given that
CRC liver metastasis are the leading cause for CRC-
related death [4] this observation promises an important
clinical impact. The effectiveness of Sal in vivo has been
described before predominantly in subcutaneous tumor
models [1, 7, 17, 26, 29–31]. Our data demonstrate the
effectiveness of Sal in clinical relevant CRC models for
the first time in a convincing extent.
Next, we gained to dissect a molecular mechanism of
Sal. Based on the observation that Sal reduces the CD133+
and therewith stem-like cell signature subpopulations of
human CRC cells [5], we investigated if the mode of action
of Sal in CD133+ and CD133- cells varies. We focused on
Wnt signaling in human CD133+ and CD133- CRC cell
lines given that aberrations in Wnt signaling cascade and
its impact on CRC development are well known [9, 10,
32–34]. Additionally, the inhibitory effect of Sal on Wnt
signaling has been described in other tumor entities before,
including leukemia, breast, pancreatic, prostate, and lung
cancer cells [11, 26, 35–38]. Hence, the hypothesis that Sal-
inomycin acts as an inhibitor of Wnt signaling is not new.
On the other hand, there is no data available indicating
that Sal has an influence on Wnt signaling in CRC. The
following findings led us to the conclusion that interfer-
ence with the Wnt/β-catenin pathway might be responsible
for the pro-apoptotic effect of Sal in human CRC cells.
First, we exposed SW620 and HT29 and the CD133+/-
subpopulations of each cell line separately to Sal and
confirmed the toxic effect on all CRC cell subpopula-
tions. Interestingly, the effect of Sal on the CD133+ and
CD133- subpopulations did not differ regarding impair-
ment of proliferation and induction of apoptosis.
Next, we observed blocking of LRP6-phosphorylation
by Sal and reduced LRP6 levels in both CD133+ and
CD133- cells. The phosphorylation of the LRP6 co-re-
ceptor is crucial for the activation of the Wnt/β-catenin
pathway [11, 36] and in aberrant Wnt signaling-
associated carcinogenesis [39] of CRC. Reduced phos-
phorylation of LRP6 after exposure to Sal was first
described in chronic lymphocytic leukemia cells [36].
Our results further confirm the data obtained by Lu and
co-workers in another study on Sal and Wnt signaling.
They observed suppression of LRP6-expression in pros-
tate and breast cancer cells after Sal-treatment [37].
Additionally, they also described reduced expression of
the Wnt target genes Cyclin D1 and Survivin [37]. We
further analyzed the expression profiles of selected Wnt
target genes. Fibronectin and Lgr5 mRNA expression
were both down-regulated upon treatment with Sal in
SW620 and HT29 cells. The importance of Fibronectin
and its spliced variant extra domain A (EDA) has been
characterized as essential for the phenotype and the
tumorigenic properties of CD133+/CD44+ CRC cells
[40]. Furthermore, a correlation between Fibronectin
EDA-level and stage of disease and chemoresistance of
CRC patients was reported [40]. Given that silencing of
EDA resulted in downregulation of Wnt/β-catenin sig-
naling and the inhibitory effects of Sal on Fibronectin
expression in our study, Sal might be regarded as an in-
hibitor of the regulatory Fibronectin/Wnt/β-catenin sig-
naling loop in human CRC cells [41].
Lgr5 is a Wnt target gene that acts as a receptor for
the Wnt agonist R spondin [42, 43]. The implications of
Lgr5 expression and its tumorigenic activity in human
CRC were described before indicating a crucial role in
stem-like cells of CRC [44, 45]. Silencing of Lgr5
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resulted in reduced proliferation, migration and colony
formation and decreased tumorigenic activity in vivo
[44]. Zhou et al. reported that Sal is able to overcome
Cisplatin-resistance in human CRC cells displaying
stem-like signatures, including increased Lgr5 expres-
sion [8]. To the best of our knowledge, our study is the
first to show that treatment with Sal directly inhibits
Lgr5 expression in human CRC cells. Having in mind
the impaired tumorigenicity after silencing of Lgr5, the
toxic effect of Sal in CRC cells are plausible.
Conclusions
In summary, our results demonstrate that Sal remains a
candidate for a potential pre-clinical application for
CRC-treatment. Interference with the Wnt/β-catenin
signaling cascade and consecutive reduced expression of
the Wnt target genes Fibronectin and Lgr5 might repre-
sent a novel molecular mechanism of Sal in CRC. Fur-
ther studies in primary human CRC specimens are
necessary to delineate the implication for Sal in targeted
therapies in CRC in the future.
Appendix
Supplementary results
Salinomycin influences the cell cycle of murine CRC cells
MC38 and CT26 cells were exposed to Sal or 5-FU for
24 hours. Cell cycle analysis was based on propidium
iodide staining and analyzed by using the Mod Fit LT
software. As demonstrated in Supplementary Figure S2,
cell cycle analysis revealed equal proportions of un-
treated MC38 and CT26 cells in the G1-, G2- and S-
phases of the cell cycle. Treatment of MC38 cells with
5-FU resulted in a decreased number of cells in the G1
and G2 phases, and an increased number of cells in the
S phase. After exposure to high concentrations of Sal (5
and 10 µM), MC38 cells tended to accumulate in the G2
phase and a decreased amount in the G1 phase, while
the number of cells in the S phase was rather stable
compared to control (Additional file 7: Figure S6 A). In
contrast, treatment of CT26 cells with 5-FU resulted an
increased number of cells in the G1 phase, whereas the
proportion of cells in the G2 and S phases was de-
creased. After exposure to Sal, CT26 cells reacted with
an accumulation in the G1 phase, while the number of
cells in the S phase decreased and the proportion of cells
in the G2 phase was stable (Additional file 7: Figure S6
B). Combined treatment with Sal and 5-FU did result in
similar effects on the cell cycle (data not shown).
Additional files
Additional file 1: Figure S1. Sorting of CD133+ and CD133- human
colorectal cancer cells. SW620 and HT29 cells were stained with a
Phycoerythyrin-conjugated CD133 antibody. Signal enhancement was
performed by a two-step FASER procedure. (A + B) Representative
setups before sort of CD133+ and CD133- SW620 and HT29 cells. (C + D)
The purity of CD133+/CD133- cells was analyzed before the experiments
were performed. (TIFF 2702 kb)
Additional file 2: Table S1. Sense and anti-sense primer sequences of
Wnt target genes and housekeeping gene used for quantitative PCR
analysis. (TIFF 2702 kb)
Additional file 3: Figure S2. The impact of combined treatment with
Salinomycin and 5-FU on murine CRC cell proliferation. The effect of com-
bined treatment with Salinomycin and 5-FU on tumor cell proliferation was
performed using the WST-1 assay. Therefore, 5 × 103 MC38 (A + B) and CT26
(C + D) cells were cultured in microtitre plates in the absence or presence of
Salinomycin (1 μM, 2 μM, 5 μM and 10 μM) and 1 μM 5-FU. Treatment was
performed either for 24 h and 48 h or for another 24–48 h with fresh medium.
Results are displayed as summary of at least 3 independent experiments as
mean ± SD; * p< 0.05 and ** p< 0.001 compared with control. (TIFF 2702 kb)
Additional file 4: Figure S3. Combined treatment with Salinomycin
and 5-FU reduces migration and invasion of murine CRC cells and
induces necrotic cell death. To visualize tumor cell migration 0.5 × 106
MC38 (A) and CT26 (B) cells were cultured in 6-well plates until confluence.
A scratch was created in the middle of the monolayer and cells were
treated with Salinomycin (1 μM, 2 μM, 5 μM and 10 μM) and 1 μM 5-FU.
Cell migration was assessed by phase-contrast microscopy and images
were captured at the beginning of treatment and after 24 and 48 h at a
magnification of 100. The open wound area after 48 h in cultured MC38
(C) and CT26 cells (D) was calculated and displayed as a summary of 3
independent experiments as mean ± SD; ** p < 0.001 compared with
control. For transwell-analysis of tumor cell migration 1 × 105 MC38 or
CT26 cells were seeded in 6-well plates equipped with a transwell insert
and exposed to Salinomycin (1 μM, 2 μM, 5 μM and 10 μM) and 1 μM
5-FU. After 48 h membranes were stained with crystal violet solution
and migrated cells were isolated from the lower side of the membrane
and quantified by ELISA reader (E + F). Alternatively, MC38 and CT26
were cultured in Matrigel-coated transwell inserts. After 48 h or further incu-
bation for another 48 h with fresh culture medium the number
of invasive migrated cells was quantified as described above (G + H). Results
are shown as representative images of stained membranes at a magnifica-
tion of 100 or as summary of at least 3 independent experiments as mean
± SD; * p < 0.05 and ** p < 0.001 compared with control. For detection of
cell death 0.5 × 106 MC38 (I) or CT26 (J) cells were seeded in 6-well plates
and grown until confluence following exposure to Salinomycin (1, 2, 5 and
10 μM) and 1 μM 5-FU for 24 h. Detection of cell death was performed
using AnnexinV-FITC and PI staining and cells analyzed by flowcytometry.
Results are displayed as representative dot blots or as summary of at least 3
independent experiments; ** p < 0.001 compared with control. (ZIP 370 kb)
Additional file 5: Figure S4. Salinomycin interferes with Wnt signaling
in HT20 CD133+/- cells. The impact of Salinomycin treatment on the
Wnt/β-catenin signaling pathway in HT29 CD133+/CD233- cells was
investigated. For protein expression analysis 1 × 106 total HT29 (A),
HT29-CD133+ (B) or HT29-CD133- (C) cells were cultured in 6-well plates
in the absence or presence of 1 μM 5-FU or increasing concentrations
of Salinomycin (1 μM, 2 μM, 5 μM and 10 μM). After protein extraction
western blotting was performed using specific antibodies against total
LRP6 and phosphorylated (P-LRP6). (TIFF 2702 kb)
Additional file 6: Figure S5. mRNA expression pattern of Cyclin D1
and LEF1 after treatment with Salinomycin. The mRNA expression levels
of Cyclin D1 (A + B) and LEF1 (C + D) in CD133+CD133- SW620 and
CD133+/CD133- HT29 cells were measured by quantitative PCR after
treatment with1 μM 5-FU or increasing concentrations of Salinomycin
(1 μM, 2 μM, 5 μM and 10 μM). (TIFF 2702 kb)
Additional file 7: Figure S6. Salinomycin influences the cell cycle of
murine CRC cells. For cell cycle analysis 1 × 103 MC38 or CT26 cells were
seeded in 6-well plates and grown until confluence and then further cultured
with medium, 1 μM FU and 5 or 10 μM Salinomycin for 24 h. After the end
of treatment, cells were stained with PI and analyzed by flowcytometry.
Sal-treatment resulted in a accumulation in the G2 phase in MC38 cells and
accumulation in the G1 phase in CT26 cells, respectively. Results are
summarized of at least 3 independent experiments. (TIFF 2702 kb)
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